Maple Research Labs Maple Research Labs
Packaged and shipped from British Columbia
COAs published for tested samples
3rd-Party COAs Available
Ships with Tracking
Menu
Browse Research Compounds
,

Retatrutide

$90.00

Research Compound Summary
Purity: 99.6% HPLC-MS/MS chromatographic relative area on the tested 10mg sample (report lot field 082126), not lot or batch verification
Net content: 10.82 mg measured against a 10 mg label (108.2%)
COA: Report: COA-2026-SC-01772, View PDF · verify at the lab
Form / size: Lyophilized · 10mg (also 20mg / 60mg; the published report covers a 10mg sample only)
Ops: Packaged and shipped from British Columbia · Same-day dispatch by 2 PM PT, Mon–Fri
CAS: 2381089-83-2
Status: Research use only, not for human consumption

The analysis report is published by the testing laboratory, SideChain Analytics, not by us. Use the lab link above, or enter report number COA-2026-SC-01772 at sidechainanalytics.com, to confirm the certificate is authentic and download the original PDF from the lab.

99.6% HPLC-MS/MS · Result for the 10mg sample tested Sep 1, 2026. Report COA-2026-SC-01772. View the report. The 20mg and 60mg sizes have no published report yet.

Check the sample report
The analysis report is published by the testing laboratory, not by us. Open the laboratory’s own verification page for report COA-2026-SC-01772, or enter the report number yourself at sidechainanalytics.com. Use the laboratory’s verification page, where available, to check the report’s current status. The report describes only the received sample, not any lot, batch or other supplied vial. Not our page, not our claim to make.

Canadian shipping: $9.95 flat, free at $350+ after discounts.

For research purposes only. Not for human consumption. Not for human or veterinary use; not for diagnostic or therapeutic use.

Retatrutide Canada from Maple Research Labs is a lyophilized triple agonist research peptide (GLP-1R / GIPR / GCGR), supplied at 10mg per vial. SideChain Analytics report COA-2026-SC-01772 describes a received Retatrutide sample analysed by HPLC-MS/MS (Liquid Chromatography Tandem Mass Spectrometry): 99.6% chromatographic relative-area purity and 10.82 mg measured net peptide content against a 10 mg label, with identity confirmed against a reference standard. The report lists 082126 in its lot field; it expressly does not verify any lot, batch or other supplied vial. The published COA is on this page and can be checked on the laboratory’s own site. Compounds are packaged and shipped from British Columbia. In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.

Product Specifications

  • Alternative Names: LY-3437943, GGG Tri-Agonist
  • Receptor Targets: GLP-1R, GIPR, GCGR
  • Molecular Formula: C221H342N46O68
  • Molecular Weight: 4731.3 g/mol
  • Purity: 99.6% HPLC-MS/MS chromatographic relative area on the tested sample (report COA-2026-SC-01772; report lot field 082126), not lot or batch verification
  • Form: Lyophilized powder
  • Quantity: 10mg per vial

Retatrutide Peptide Canada Research Summary

Retatrutide (LY-3437943) is a synthetic peptide developed as a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple agonist approach distinguishes retatrutide peptide Canada research products from dual agonists such as tirzepatide (GLP-1R/GIPR) and single agonists such as semaglutide (GLP-1R only).

The rationale for triple agonism is based on preclinical research demonstrating that glucagon receptor activation contributes to energy expenditure and lipid metabolism through distinct mechanisms from those engaged by GLP-1R and GIPR agonism. Published research suggests that the addition of glucagon receptor activity to the GLP-1/GIP agonist profile may produce metabolic effects not achievable through dual agonism alone.

Mechanism of Action Research

Retatrutide’s triple agonist profile engages three distinct G protein-coupled receptors with complementary downstream signaling effects studied in preclinical models. GLP-1R is a class B G protein-coupled receptor studied in incretin signalling research. GIPR agonism contributes to glucose-dependent insulin release and may modulate adipose tissue metabolism. GCGR agonism activates hepatic gluconeogenesis and glycogenolysis pathways, and research suggests it increases energy expenditure through thermogenic mechanisms.

The structural design of retatrutide incorporates modifications that allow simultaneous engagement of all three receptor systems with distinct potency ratios. Published binding affinity studies have characterized the peptide’s relative activity at each receptor, with the highest potency reported at the GIPR, followed by GLP-1R and GCGR.

Preclinical pharmacokinetic studies have examined the peptide’s metabolic stability, half-life characteristics, and receptor occupancy patterns in animal models. The compound incorporates fatty acid modifications designed to extend circulating half-life through albumin binding, similar to approaches used in other long-acting peptide agonists.

Preclinical Study Summary

Retatrutide has been investigated in multiple preclinical metabolic research models. Published studies have examined its effects on glucose homeostasis, lipid metabolism, body composition, and energy expenditure in rodent and non-human primate models. The triple agonist mechanism represents a newer area of incretin biology research compared to established single and dual agonist compounds.

All findings referenced are from preclinical research and early-phase investigations. Researchers should consult primary literature for complete experimental protocols.

References

Retatrutide Canada Quality Assurance

Consult available sample-specific analytical documentation; a report alone does not establish current shipping-lot coverage or a universal release process. A received sample (report lot field 082126) measured 99.6% chromatographic relative-area purity by HPLC-MS/MS (report COA-2026-SC-01772), with identity confirmed against a reference standard and 10.82 mg net peptide content against the 10 mg label, a fill accuracy of 108.2%. Published sample reports alone do not establish the lot or analysis of a specific supplied vial. Vials do not carry printed lot or batch numbers.

Storage and Handling

Store lyophilized at -20C. Avoid freeze-thaw cycles and light exposure.

Shipping

In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.

Certificate of Analysis (COA)

Testing Laboratory SideChain Analytics, Mississauga, Ontario (independent third-party laboratory)
Report Number COA-2026-SC-01772
Report lot field 082126
Method HPLC-MS/MS (Agilent 1290 Infinity II with 6495 triple quadrupole)
Identity Retatrutide, principal component confirmed against reference standard
Purity (HPLC-MS/MS) 99.6%
Net Content / Fill Accuracy 10.82mg measured / 10.00mg label (108.2%)
Date Analyzed September 1, 2026
Download COA Download Full COA (PDF)
Verify at the Lab Open the laboratory’s verification page for this report, or enter the report number at sidechainanalytics.com

Results are for the sample the laboratory received, reported as measured. The original PDF is also served by the laboratory from its own verification page.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research Articles

Frequently Asked Questions

What is the CAS number for Retatrutide?

The CAS registry number for Retatrutide is 2381089-83-2. It is a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors.

How is Retatrutide purity reported on the published COA?

Published COA for a tested sample (report COA-2026-SC-01772, SideChain Analytics, HPLC-MS/MS) lists 99.6% chromatographic relative-area purity with identity confirmed against a reference standard for that sample. The report does not verify any lot, batch or other supplied vial. The full COA PDF is on this page, and the laboratory confirms the same certificate on its own verification page.

Is Retatrutide available in Canada for research?

Maple Research Labs supplies Retatrutide as a research-use-only lyophilized peptide from British Columbia, with a published COA for a tested sample linked on this page. It is not a Health Canada-authorized drug and is not for human use.

How do I verify the Retatrutide COA?

Open the PDF on this page (report COA-2026-SC-01772), then check it against the laboratory: open the verification page for this report or enter the report number at sidechainanalytics.com. The lab confirms the certificate is authentic and serves the original PDF from its own site.

When does Retatrutide Canada ship?

In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.

How should Retatrutide be stored?

Store lyophilized at -20C. Retatrutide is a large peptide (molecular weight ~4,731 Da) and should be handled with standard peptide storage protocols. Avoid freeze-thaw cycles and light exposure.

Related Research Peptides from Maple Research

Researchers may also be interested in Tesamorelin 5MG, Ipamorelin 5MG, and MOTS-C 10MG. See each product’s available analytical documentation and tested-sample results in the COA index. In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.

Join the research list

New arrivals, current pricing, and research breakdowns, every few days. Unsubscribe anytime.

Size

10mg, 20mg, 60mg

Pack size

Single vial, 10-pack

You may also like…

Shopping Cart

Maple Research Labs

Canadian supplier of high-purity research compounds for laboratory and scientific applications.

Packaged and shipped from British Columbia

[email protected]
For Research Purposes Only. All products sold by Maple Research Labs are intended for laboratory research use only. Not for human consumption.
© 2026 Maple Research LabsPrivacy Policy | Legal | Refund and Returns Policy | Terms
Scroll to Top